Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pantoprazole is a first-generation proton pump inhibitor (PPI) used to treat conditions involving excessive gastric acid production. Its primary indications include gastroesophageal reflux disease (GERD), erosive esophagitis, and pathological hypersecretory conditions such as Zollinger-Ellison syndrome. Pantoprazole works by irreversibly binding to and inhibiting the H+/K+ ATPase enzyme (the gastric proton pump) in the parietal cells of the stomach, thereby blocking the final step in gastric acid secretion. This inhibition leads to a significant and prolonged reduction in stomach acid production[1][2][3][4][6]. The drug is metabolized mainly by CYP2C19 and CYP3A4 enzymes in the liver[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pantoprazole.